SonaCare Medical, LLC

SonaCare Medical, LLC is dedicated to developing innovative medical technologies, particularly the Sonablate HIFU device, which offers a minimally-invasive solution for prostate treatment, enhancing patient care through advanced ultrasound technology. Founded in 2004 in Charlotte, US, SonaCare Medical, LLC specializes in minimally-invasive prostate cancer treatments. Under the leadership of CEO Richard Yang, the company has raised a total of USD 3. 00 mn in funding, with the latest Growth round occurring on August 3, 2017, led by Decathlon Capital Partners.

The company has remained focused on its original business strategy without any noted pivots. SonaCare Medical, LLC focuses on the Sonablate HIFU (High-Intensity Focused Ultrasound) device, which provides a minimally-invasive alternative for prostate cancer treatment. The device utilizes real-time ultrasound feedback for precise ablation of prostate tissue, ensuring patient safety through features like Tissue Change Monitoring and Total Acoustic Power. It has received approvals in over 50 countries, including FDA clearance in the United States, catering to healthcare providers, urologists, and hospitals across North America, Europe, and selected Asian markets.

SonaCare Medical, LLC generates revenue primarily through the sales of the Sonablate HIFU device to healthcare institutions and professionals treating prostate diseases. The company operates a direct-to-consumer model, where physicians order the device for clinical use, often bundled with training and support services. Additional revenue may stem from partnerships with medical institutions enhancing their focal therapy programs, supported by the advanced technology and efficacy of the Sonablate HIFU device. SonaCare Medical, LLC plans to utilize the USD 3.

00 mn raised in its most recent Growth funding round to expand its product line and market reach. The company is actively developing new products to enhance treatment options and aims to penetrate new geographic markets, with a focus on expanding its presence in Europe and select Asian regions by 2025. This strategic investment will facilitate the launch of innovative solutions and support entry into these targeted markets.